Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
<Research>JPM Names AKESO/ HANSOH PHARMA/ WUXI APPTEC as Top Picks; Pharma Pullback Provides Tailwinds for Next Yr
Recommend 10 Positive 14 Negative 4 |
||||
|
||||
|
China healthcare stocks have been experiencing a noticeable pullback since the beginning of October, with the Hang Seng Healthcare Index and the CSI 300 Healthcare Index declining by 12% and 9% respectively, compared to a 2% drop in the HSI and a 1% rise in the CSI 300 Index, JPMorgan noted in its research report. This pullback can be attributed to multiple factors, including heightened US-China tensions, intensified geopolitical risk premiums prompting investors to take profits, and the inclusion of a milder version of the US Biosecure Act into next year's National Defense Authorization Act sparking uncertainties for pharmaceutical outsourcing services. JPMorgan believes this stock price pullback will provide tailwinds for next year's performance. The broker's top picks include AKESO (09926.HK), HANSOH PHARMA (03692.HK), and WUXI APPTEC (02359.HK). It is also optimistic about INNOVENT BIO (01801.HK) and HENGRUI PHARMA (01276.HK). AAStocks Financial News |
||||
Copied to Clipboard
 |
||||
